Collegium Pharmaceutical Inc Stock Price, News & Analysis

Collegium Pharmaceutical (Nasdaq: COLL) announced its participation at the H.C. Wainwright Global Investment Conference, scheduled for May 23-26, 2022, at the Fontainebleau Miami Beach Hotel. Collegium’s presentation is set for May 24, 2022, at 3:30 pm ET. The company is focused on improving the lives of those with serious medical conditions and is headquartered in Stoughton, Massachusetts. For more information, visit www.collegiumpharma.com.

Collegium Pharmaceuticals reported Q1 2022 net revenue of $83.8 million, down from $87.7 million in Q1 2021. The BDSI acquisition is on track to exceed targeted run rate synergies of $75 million. The company has resolved all opioid-related litigation and provided financial guidance for 2022, expecting revenues between $450 million and $465 million. Despite a net loss of $13.1 million this quarter, Collegium’s outlook remains positive with a cash balance of $106.7 million.

Collegium Pharmaceutical (Nasdaq: COLL) will host a conference call on May 10, 2022, at 4:30 p.m. ET, to discuss its Q1 2022 financial results and provide a corporate update. Interested parties can join by dialing (877) 407-8037 for U.S. callers or (201) 689-8037 for international callers. The call will also be available via a live audio webcast on the company’s website, with replays accessible two hours after the event.

Collegium is dedicated to enhancing the lives of those with serious medical conditions, headquartered in Stoughton, Massachusetts.

Collegium Pharmaceutical (Nasdaq: COLL) announced its participation in the 21st Annual Needham Virtual Healthcare Conference, set for April 13, 2022. Management will engage in a virtual fireside chat, which will be webcast and accessible through the investor section of the company's website. A replay will be available for 30 days following the event. Collegium is dedicated to enhancing the lives of those with serious medical conditions, headquartered in Stoughton, Massachusetts. For more details, visit www.collegiumpharma.com.

Collegium Pharmaceutical (Nasdaq: COLL) announced the appointment of Neil F. McFarlane to its Board of Directors, effective April 6, 2022. McFarlane brings extensive experience from previous leadership roles at Adamas Pharmaceuticals and Retrophin. The Chairman, Mike Heffernan, expressed confidence in McFarlane's ability to provide valuable insights and contributions. This strategic addition comes as the company aims to enhance its operations and improve the lives of individuals with serious medical conditions.

Collegium Pharmaceutical (Nasdaq: COLL) has updated its financial guidance for 2022 following the acquisition of BioDelivery Sciences International on March 22, 2022. Expected total product revenues are projected between $450.0 million and $465.0 million, reflecting a 65% increase from $276.9 million in 2021. Adjusted operating expenses are estimated at $130.0 million to $140.0 million and adjusted EBITDA is expected to reach $235.0 million to $250.0 million. The company aims for operational synergies of at least $75 million as it integrates BDSI.

Collegium Pharmaceutical, Inc. (Nasdaq: COLL) has reached a Master Settlement Agreement to resolve 27 opioid-related lawsuits without admitting liability. Executed on March 18, 2022, the company has paid $2.75 million to the plaintiffs, leading to case dismissals anticipated in the upcoming weeks. This settlement follows a previously announced framework from December 2021, marking a strategic decision to mitigate legal risks. Collegium aims to strengthen its position as a specialty pharmaceutical company focused on aiding patients with serious medical conditions.

Collegium Pharmaceutical (Nasdaq: COLL) has completed its acquisition of BioDelivery Sciences International (Nasdaq: BDSI) for $5.60 per share, totaling approximately $40 million. This strategic move aims to enhance Collegium's revenue through diversification, adding products like BELBUCA and ELYXYB to its portfolio. The acquisition is expected to yield annual synergies of at least $75 million within the first year, strengthening Collegium's financial position and accelerating cash flow generation, while expanding its footprint in the neurology market.

Collegium Pharmaceutical (Nasdaq: COLL) reported its Q4 and full-year 2021 financial results, revealing a net loss of $25 million for Q4 and $71.5 million net income for the full year. The company anticipates 2022 revenues between $315 million and $330 million, driven by growth in Xtampza ER. They expect the BDSI acquisition to close in late Q1 2022, aiming for synergies exceeding $75 million. Despite challenges, Collegium ended 2021 with a cash balance of $186.4 million and achieved significant market share gains in Xtampza ER, with a 33% share of the oxycodone extended-release market.